> ## Content Index
> Fetch the complete content index at: https://morpheus-research-labs.ghost.io/llms.txt
> Use this file to discover other available public pages before exploring further.

# How Receptor Binding Assays Work: Kd, Ki, IC50 and Reading Peptide Binding Data
- URL: https://morpheus-research-labs.ghost.io/receptor-binding-assays-explained/
- Published: 2026-11-04T16:07:25.000Z
- Updated: 2026-11-04T16:07:25.000Z
- Description: A plain guide to receptor binding assays in peptide research: saturation and competition formats, Kd, Bmax, IC50, Ki, the Cheng-Prusoff equation and common pitfalls.
- Author: Morpheus Research
- Tags: Pharmacology, Assays, Peptide Research

When a paper says a peptide binds a receptor "with nanomolar affinity," that number almost always comes from a receptor binding assay. Binding assays are one of the oldest and most widely used tools in pharmacology, and they sit underneath much of the published peptide literature. This guide explains what they measure, how the main formats work, and how to read the numbers without over-reading them.

## What a binding assay measures

A binding assay measures how strongly a molecule (the ligand) sticks to its target (usually a receptor) and how many binding sites are present. It does not, on its own, tell you what happens after binding. A ligand can bind tightly and activate the receptor (an agonist), bind tightly and block it (an antagonist), or bind and do very little. Questions about activation are answered by separate functional assays, such as measuring cAMP or calcium signals in cells.

Binding is a reversible reaction: ligand plus receptor forms a ligand–receptor complex, which can come apart again. At equilibrium, the balance between binding and unbinding is described by the **equilibrium dissociation constant, Kd**. Kd is the ligand concentration at which half the receptors are occupied. A smaller Kd means tighter binding.

## The ingredients

A typical assay uses:

- **A receptor source.** Cell membranes from cells engineered to express the receptor, tissue membranes, whole cells or purified receptor.
- **A labelled ligand.** Traditionally a radioligand (a ligand tagged with an isotope such as iodine-125 or tritium). Fluorescent and luminescent labels are increasingly common.
- **A way to separate bound from free ligand.** Rapid filtration through glass-fibre filters is the classic method. Homogeneous formats such as scintillation proximity assays or fluorescence polarization skip the separation step.

## Total, non-specific and specific binding

Labelled ligand doesn't only stick to the receptor. Some sticks to the filter, the plastic and other membrane proteins. To account for that, each condition is measured twice:

- **Total binding:** labelled ligand alone.
- **Non-specific binding:** labelled ligand plus a large excess of unlabelled ligand, which fills the real receptor sites so only the background remains.

**Specific binding = total − non-specific.** Good assays have specific binding that is a large share of the total. When non-specific binding dominates, the results get noisy and unreliable.

## Saturation binding: Kd and Bmax

In a saturation experiment, the amount of receptor is fixed and the concentration of labelled ligand is increased step by step. Specific binding rises and then levels off as the receptors fill up. Fitting that curve gives two numbers:

- **Kd**, the affinity of the labelled ligand.
- **Bmax**, the total number of binding sites, often expressed per milligram of membrane protein.

Historically, data were linearised with the Scatchard plot, introduced by George Scatchard in 1949\. Today non-linear regression on the raw curve is preferred, because linear transformations distort experimental error. The Scatchard plot is still useful as a visual check.

## Competition binding: IC50 and Ki

Most peptide papers report competition data. Here the labelled ligand is held at one concentration, and increasing concentrations of an unlabelled test compound (say, a new peptide analogue) are added. As the test compound occupies more receptors, labelled binding falls. The concentration that displaces half the specific binding is the **IC50**.

IC50 is not a fixed property of the compound. It depends on how much labelled ligand was used and how tightly that ligand binds. To compare across experiments, IC50 is converted to the **inhibition constant, Ki**, using the Cheng–Prusoff equation (Cheng and Prusoff, 1973):

**Ki = IC50 / (1 + \[L\]/Kd)**

where \[L\] is the labelled ligand concentration and Kd is its affinity. Ki estimates the affinity the test compound would show on its own, which makes it the better number to compare between labs. The equation assumes simple competitive binding at a single site at equilibrium, so it's only as good as those assumptions.

## Kinetics: on and off rates

Binding can also be followed over time. The association rate (kon) and dissociation rate (koff) describe how fast the complex forms and falls apart, and koff/kon gives a kinetic estimate of Kd. Residence time, or how long a ligand stays bound, has become an active research topic because two compounds with the same Kd can behave quite differently if one dissociates much more slowly.

## Pitfalls to watch for

Hulme and Trevethick's 2010 review in the *British Journal of Pharmacology* is a standard reference on doing and interpreting these assays well. Common problems include:

- **Not reaching equilibrium.** High-affinity peptides can take a long time to equilibrate, especially at low concentrations. Stopping too early underestimates affinity.
- **Ligand depletion.** If the receptor binds a large share of the added ligand, the "free" concentration is lower than assumed and the maths breaks down.
- **Peptide adsorption.** Peptides can stick to plastic and glass, lowering the real concentration. Carrier proteins such as BSA are often added to the buffer for this reason.
- **Peptide degradation.** Proteases in membrane preparations can break peptides down during incubation. Protease inhibitors are often included.
- **Material quality.** An impure or mis-quantified peptide gives a wrong concentration and therefore a wrong IC50\. Purity and identity data ([HPLC and mass spectrometry](https://morpheus-research-labs.ghost.io/hplc-vs-mass-spectrometry-peptide-testing/)), net peptide content and proper [storage](https://morpheus-research-labs.ghost.io/how-to-store-research-peptides/) all feed directly into binding results.

## Reading binding data in papers

When you see an affinity value, it's worth asking a few questions. Was it Ki, IC50 or Kd? What receptor source and species was used? Was the labelled ligand an agonist or antagonist, since some receptors show different affinity states? How many independent experiments were run? Affinity values for the same peptide can differ several-fold between labs for entirely technical reasons, so comparisons are most meaningful within the same study.

## Frequently asked questions

**What's the difference between Kd and Ki?** Kd is usually measured directly for the labelled ligand. Ki is the affinity of an unlabelled competitor, calculated from its IC50.

**Why isn't IC50 enough?** IC50 changes with assay conditions, especially the concentration and affinity of the labelled ligand. Ki corrects for those conditions.

**Does high affinity mean a peptide is an agonist?** No. Binding assays measure attachment, not activity. Functional assays are needed to tell agonists from antagonists.

**Do binding assays always use radioactivity?** No. Fluorescence-based and label-free methods, such as surface plasmon resonance, are widely used alongside radioligand assays.

## Related reading

- [HPLC vs Mass Spectrometry: What Peptide Purity Testing Actually Shows](https://morpheus-research-labs.ghost.io/hplc-vs-mass-spectrometry-peptide-testing/)
- [Endotoxin Testing for Research Peptides](https://morpheus-research-labs.ghost.io/endotoxin-testing-research-peptides/)
- [Peptide COA Explained](https://morpheus-research-labs.ghost.io/peptide-coa-explained/)

*All materials discussed are for laboratory research use only.*

## References

- Scatchard G. The attractions of proteins for small molecules and ions. *Annals of the New York Academy of Sciences.* 1949;51(4):660-672\. doi:10.1111/j.1749-6632.1949.tb27297.x.
- Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. *Biochemical Pharmacology.* 1973;22(23):3099-3108\. doi:10.1016/0006-2952(73)90196-2.
- Hulme EC, Trevethick MA. Ligand binding assays at equilibrium: validation and interpretation. *British Journal of Pharmacology.* 2010;161(6):1219-1237\. doi:10.1111/j.1476-5381.2009.00604.x.